Invion appoints experts to its Scientific Advisory Board

Company News

by Anna Napoli

Cancer therapy developer, Invion (ASX:IVX) has strengthened its scientific advisory board appointing experts in skin, lung and prostate cancer.

New appointees include, Dr Lynda Spelman, Assoicate Professor Louis Irving and Associate Professor Nathan Lawrentschuk.

Invion says the appointments will advance clinical development and help ensure that the Invion drugs and devices are optimized for each cancer type.

The company is developing photodynamic therapies for a range of cancers including skin, ovarian prostate and lung cancer.

Shares in Invion (ASX:IVX) last traded at 6 cents.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.